Immunovia publishes the Annual Report for 2024

Rhea-AI Summary

Immunovia AB (IMMNOV: Nasdaq Stockholm) has announced the publication of its Annual Report for 2024. The company specializes in diagnostic solutions focused on increasing pancreatic cancer survival rates through early detection using blood-based testing technology.

Immunovia's primary market is the United States, where an estimated 1.8 million individuals are considered high-risk for pancreatic cancer and could benefit from annual surveillance testing. The company develops tests to detect specific proteins and antibodies that indicate pancreatic cancer development in high-risk individuals, working closely with healthcare providers, experts, and patient advocacy groups.

Positive

• Large addressable market with 1.8 million potential high-risk individuals in the US

Negative

• None.

LUND, Sweden, April 2, 2025 /PRNewswire/ -- Immunovia AB (publ) today announced that the Annual Report for 2024 has been published.

The annual report can be downloaded in pdf format and is available on Immunovia's website.

For more information, please contact:

Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com  

Immunovia in brief 

Immunovia AB (IMMNOV: Nasdaq Stockholm), is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. 

Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer. 

USA is the world's largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing. 

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/immunovia-ab/r/immunovia-publishes-the-annual-report-for-2024,c4129259

The following files are available for download:

https://mb.cision.com/Main/13121/4129259/3361494.pdf

Annual Report 2024

 

View original content:https://www.prnewswire.com/news-releases/immunovia-publishes-the-annual-report-for-2024-302418139.html

SOURCE Immunovia AB

FAQ

What is the main focus of Immunovia's (IMMNOV) diagnostic technology?

Immunovia focuses on developing blood-based tests to detect proteins and antibodies that indicate pancreatic cancer in high-risk individuals for early detection.

How many people could benefit from Immunovia's (IMMNOV) pancreatic cancer testing in the USA?

According to company estimates, 1.8 million high-risk individuals in the USA could benefit from annual pancreatic cancer surveillance testing.

Where are Immunovia's (IMMNOV) shares listed?

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm.

When did Immunovia (IMMNOV) publish its latest Annual Report?

Immunovia published its Annual Report for 2024 on April 2, 2025.